1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsopenAACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga is sponsored by American Association for Cancer Research (AACR) and AstraZeneca. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
AACR-AstraZeneca Career Development Award for Physician-Scientists, in honor of José Baselga - American Association for Cancer Research (AACR) Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off.
Patient / Caregivers / Public Researchers / Professionals Home > Cancer Researchers / Other Health Care Professionals > Research Funding > Funded Research > Career Development Awards > AACR-AstraZeneca Career Development Award for Physician-Scientists, in honor of José Baselga AACR-AstraZeneca Career Development Award for Physician-Scientists, in honor of José Baselga The AACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga has been established to honor the life and legacy of Dr. José Baselga, who was a scientific leader and supportive mentor to an entire generation of physician-scientists.
The intent of this program is to encourage and support junior physician-scientists to conduct research and bolster the development of innovative targeted therapeutics. Jennifer Y. Y.
Kwan, MD, PhD, FRCPC Radiation Oncologist-Clinician Scientist University Health Network Targeting of PPAR signaling to treat cancer-related lymphedema Progression and irreversibility of cancer-related lymphedema, a major long-term side effect of cancer treatment, can be primarily attributed to fibrosis. Downregulation of peroxisome proliferator-activated receptor (PPAR) signalling is a hallmark pathology in this condition.
In this research, Dr. Kwan plans to uncover the critical genes and cell types facilitating the development of fibrosis via the PPAR signaling pathway, and to identify a new treatment strategy to target mediators of fibrosis in cancer-related lymphedema. Treating this condition can enhance the therapeutic ratio of cancer treatments by reducing toxicity and improving the tolerability of cancer treatment.
Dr. Kwan received her medical degree from Queen’s University and completed her doctorate and radiation oncology residency training at the University of Toronto. She was also a scholar of the Royal College Clinician Investigator Program (CIP) and Strategic Training in Transdisciplinary Radiation Science for the 21st Century (STARS21) Program.
She is currently a radiation oncologist-clinician scientist at the Princess Margaret Cancer Centre and an assistant professor in the Department of Radiation Oncology and the Institute of Medical Science at the University of Toronto. Her research program focuses on novel biomarkers and therapeutics for side effects of cancer treatment.
Acknowledgment of Support “I am honored to receive the AACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga. This is a significant milestone in my early career as a physician-scientist. The award will allow us to reach our full potential in minimizing side effects of cancer treatments for our patients.
” Children’s Hospital of Philadelphia Philadelphia, Pennsylvania, USA Murine GPC2 CAR T cells to define mechanisms of immune escape Glypican 2 (GPC2) is an oncoprotein found on neuroblastoma, but not normal, tissues. The Bosse laboratory has developed human GPC2 CAR T cells that are being tested in a first-in-human Phase 1 clinical trial.
In parallel, to define the role of the tumor immune microenvironment in GPC2 CAR efficacy, they developed paired-murine GPC2 CARs and performed studies in immunocompetent neuroblastoma allograft models. Results of these studies suggest that limited CAR T cell tumor trafficking and enhanced tumor infiltration of immunosuppressive myeloid-derived suppressor cells (MDSCs) may be mechanisms of GPC2 CAR immune escape.
To explore these putative mechanisms further, Dr. Bosse is set to: 1) characterize how MDSCs modulate GPC2 CAR T cells, 2) develop CXCR2-armored GPC2 CARs to enhance CAR T cell tumor trafficking and circumvent MDSC-mediated immune suppression, and 3) utilize serial blood samples from their Phase 1 trial to define the relationship between MDSCs and GPC2 CAR T cell persistence and efficacy in patients with neuroblastoma.
Dr. Bosse graduated summa cum laude with honors from Bowdoin College, and completed his medical degree and training at University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP). He began studying neuroblastoma as a Howard Hughes Medical Institute Fellow during medical school. He is currently an Assistant Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania and CHOP.
Dr. Bosse’s laboratory at CHOP is currently focused on using an integrated genomic and functional approach to identify novel cell surface molecules for immunotherapeutic targeting in neuroblastoma and other pediatric cancers.
Acknowledgement of Support “Receiving a 2023 AACR-AstraZeneca Career Development Award for Physician Scientists, in Honor of José Baselga, is a tremendous honor and will allow us to define mechanisms of glypican 2 CAR T cell immune escape to enable development of more potent immunotherapies for children with cancer.
” Whitehead Fellow Whitehead Institute for Biomedical Research Unbiased Discovery of Macrophage-Directed Immunotherapies for Cancer Macrophages are often the predominant infiltrating immune cell in tumors, yet their potential to act as effectors of cancer immunotherapy has been underappreciated.
The CD47/SIRPa interaction is a macrophage immune checkpoint, and therapies that block this interaction demonstrate the tremendous potential of macrophages to attack cancer. However, the receptors and signaling pathways that regulate macrophage activation against cancer remain poorly understood relative to other immune cell types.
In this study, Dr. Weiskopf takes an unbiased approach to identify novel immune checkpoints that regulate macrophages in the tumor microenvironment. Moreover, he will employ a multi-pronged strategy to discover new small molecules and biologics that activate macrophages to attack cancer. Kipp Weiskopf, MD, PhD earned his medical and graduate degrees at Stanford University.
As a member of Irving Weissman’s laboratory, he characterized the CD47/SIRPa axis as a macrophage immune checkpoint. He previously trained at Brigham and Women’s Hospital and is board-certified in Internal Medicine. He is currently a Valhalla Fellow at Whitehead Institute for Biomedical Research, where he leads a research laboratory focused on macrophage-directed therapies for cancer.
He is concurrently appointed as a medical oncology fellow at Dana-Farber Cancer Institute. He is an inventor on over 15 U.S. patents and is a cofounder of ALX Oncology. Acknowledgment of Support Dr. Baselga was a champion of cancer research and a fierce advocate for cancer patients.
It is a tremendous honor to be supported by this award, which memorializes Dr. Baselga’s lifetime of contributions to oncology. Drawing inspiration from his example, I strive for our research to be transformative for patients. block needs to be placed in the location where the link block will be displayed--> Career Development Awards AACR Career Development Award in Lung Cancer Research AACR-Conquer Cancer®, the ASCO Foundation...
According to the current listing, eligibility includes: Individual physician-scientists at all career stages. Confirm the full requirements in the official notice before applying.
The current listing shows $300,000 over 3 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
openAACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga is funded by American Association for Cancer Research (AACR) and AstraZeneca. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article